Last reviewed · How we verify

Haemophilus b Conjugate Vaccine

Sanofi Pasteur, a Sanofi Company · FDA-approved active Biologic Quality 5/100

Haemophilus b Conjugate Vaccine is a Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently FDA-approved.

Haemophilus b Conjugate Vaccine, marketed by Sanofi Pasteur, holds a significant position in the pediatric vaccine market. The key composition patent is set to expire in 2028, providing a strong competitive barrier until then. The primary risk lies in potential generic competition post-patent expiry, which could erode market share and revenue.

At a glance

Generic nameHaemophilus b Conjugate Vaccine
SponsorSanofi Pasteur, a Sanofi Company
ModalityBiologic
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Haemophilus b Conjugate Vaccine

What is Haemophilus b Conjugate Vaccine?

Haemophilus b Conjugate Vaccine is a Biologic drug developed by Sanofi Pasteur, a Sanofi Company.

Who makes Haemophilus b Conjugate Vaccine?

Haemophilus b Conjugate Vaccine is developed and marketed by Sanofi Pasteur, a Sanofi Company (see full Sanofi Pasteur, a Sanofi Company pipeline at /company/sanofi).

What development phase is Haemophilus b Conjugate Vaccine in?

Haemophilus b Conjugate Vaccine is FDA-approved (marketed).

Related